Sunday, November 15, 2026

EUR/CHF Bearish Momentum: 0.91% Down In The Last 10 Sessions

ViaNews Editorial Team

October 10, 2023

Automated market report from our archive (2020-2024), published before source-traceability. How we work

EUR/CHF Bearish Momentum: 0.91% Down In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 0.91% for the last 10 sessions. At 14:06 EST on Tuesday, 10 October, EUR/CHF (EURCHF) is $0.96.

EUR/CHF's yearly highs and lows, it's 0.82% up from its 52-week low and 5.001% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a negative 0.10%, a positive 0.04%, and a positive 0.23%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.18% (last week), 0.24% (last month), and 0.23% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • According to FXStreet on Monday, 9 October, "The continuation of selling pressure on EUR/USD might result in a review of the 2023 low at 1.0448 seen on October 3, with a challenge of the crucial round mark of 1.0400. ", "As long as the EUR/USD remains below the 200-day SMA, additional negative pressure is possible."
  • Eur/usd price analysis: hovers above 1.0550 major level, MACD suggests momentum shift. According to FXStreet on Tuesday, 10 October, "On the upside, the EUR/USD pair could faceresistance near the major level at 1.0600 lined up with the 21-day Exponential Moving Average (EMA) at 1.0605.", "However, the prevailing bullish momentum in the EUR/USD pair indicates a bearish bias, as the 14-day Relative Strength Index (RSI) remains below the 50 level."
  • Eur/usd trades with a mild positive bias on subdued USD demand, remains below 1.0600 mark. According to FXStreet on Tuesday, 10 October, "This, along with the US bond yields and the broader risk sentiment, will drive the USD demand and contribute to producing short-term trading opportunities around the EUR/USD pair in the absence of any relevant economic data.", "This points to a well-established short-term bearish trend and makes it prudent to wait for a strong follow-through buying before confirming that the EUR/USD pair has formed a near-term bottom around the 1.0450-1.0445 area, or the YTD trough set last week. "
  • Eur/usd trades higher around 1.0570 amid palestine-Israel military conflict. According to FXStreet on Monday, 9 October, "The renewed geopolitical tensions could impact the recent surge of the EUR/USD pair. "
  • Eur/usd technical analysis: new exciting trading week - 09 October 2023. According to DailyForex on Monday, 9 October, "Expectations for the euro against the dollar today:According to the performance on the daily chart below, the price of the EUR/USD currency pair has not yet broken the general downward trend."

More news about EUR/CHF (EURCHF).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,997
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,997 facts checked against source5,580 source documents archived
Query this data → isubstrate.com